Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ulotaront gastric emptying study in schizophrenia
NCT05402111Phase 1Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Jun 2022
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ulotaront in schizophrenia (2 arms), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoints: Gastric emptying T 1/2 (gastric emptying scintigraphy) at Day 2 and Gastric retention at 4 hr post-radiolabeled meal. Started Jun 2022; status: completed.
02
Drugs
ulotaront
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT05402111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05402111.